A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

This Phase III study is testing a combination of two targeted therapies — KN026 and HB1801 — with or without a chemotherapy drug called carboplatin, given before surgery (called neoadjuvant treatment) in people with HER2-positive breast cancer. HER2-positive means the cancer cells have high levels of a protein that drives tumor growth. **You may be eligible if...** - You are 18 or older - You have been diagnosed with HER2-positive early-stage or locally advanced breast cancer (confirmed by biopsy) - Your cancer is HER2-positive by standard laboratory testing - You have an adequate performance status (able to carry out normal daily activities) - You are willing to undergo surgery after the pre-surgery treatment - You agree to use contraception if applicable **You may NOT be eligible if...** - You have cancer that has spread to distant organs (metastatic disease) - You have poor organ function (kidneys, liver, heart, or bone marrow) - You are pregnant or breastfeeding - You have had prior chemotherapy or targeted therapy for this cancer Talk to your doctor to see if this trial is right for you.